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Objective: This systematic review sought to identify the association of dietary intake and supplementation of
specific polyunsaturated fatty acids with inflammation and function in people with chronic obstructive pulmonary
disease (COPD).
Data sources: We searched electronic databases including PubMed, CINAHL, MEDLINE, EMBASE, The Cochrane
Library, ProQuest Dissertations and Theses, Scopus, Google Scholar, Trove, and WHO International Clinical Trials
Registry Platform and reference lists of retrieved articles published prior to August 2014.
Inclusion criteria: We considered observational studies that evaluated dietary intake of omega-3 (eicosapentae-
noic acid, docosahexaenoic acid or a-linolenic acid) and/or omega-6 fatty acids (g-linoleic acid or arachidonic acid),
and experimental studies that evaluated omega-3 fatty acid supplementation (containing predominantly one or more
omega-3 fatty acids) on airway and systemic inflammatory markers and/or functional capacity outcomes in people
with COPD-related diagnoses.
Data synthesis: Since statistical pooling was not possible, the findings were presented in narrative form including
tables and figures to aid in data presentation when appropriate.
Results: One 8-week randomized controlled trial conducted in 80 COPD patients in the Netherlands showed
polyunsaturated fatty acid supplementation significantly improved exercise capacity compared with the control
condition [between-group difference in mean peak workload was 9.7W (2.5–17.0; P¼ 0.009); and mean duration was
4.3min (0.6–7.9; P¼ 0.023)]. One cross-sectional study conducted in 250 COPD patients in Spain found associations of
specific dietary omega-3 fatty acids with inflammation were inconsistent.
Conclusions: Limited evidence provides weak support for the use of omega-3 fatty acid supplementation for
reducing chronic inflammation and some support for improving functional capacity in COPD patients. There is no
consistent evidence showing that low dietary intake of specific omega-3 fatty acids worsens inflammation and/or
function. More evidence is required before routinely incorporating this therapy within COPD management plans.
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C hronic obstructive pulmonary disease (COPD) iscurrently ranked the fifth leading cause of global
disability (health loss).1 The Burden of Obstructive Lung
Disease (BOLD) study estimates that the prevalence of
COPD, defined according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria asof Adelaide, Joanna Briggs Institute 1
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©2015 Ustage 2 or higher, was 7.5% among Australian people
aged 40 years or older in 2006–2010.2 The prevalence of
COPD was highest among people aged 75 years or
older.2 A recent report by Access Economics estimates
that COPD cost the Australian economy about $98 billion
in 2008.3 Since Australia’s population is ageing, the
projected rise in the health burden of COPD will
undoubtedly cause significant stress on the national
healthcare system. Effective treatments to slow the
progression of COPD and/or prevent exacerbations will
likely result in significant health and economic benefits.
Chronic obstructive pulmonary disease is character-
ized by persistent airflow limitation that is usually pro-
gressive and associated with chronic inflammation in the
airways and lungs from exposure to noxious particles or
gases.4 Prolonged exposure to noxious particles and
gases is likely to bring about a chronic (innate and
adaptive) inflammatory response in COPD patients
which increases production and accumulation of mucus,
infiltration of the airway walls by inflammatory cells,
thickening of the airway wall and narrowing of the
lumen.5 The progression of COPD (i.e. an increase in
the severity of airflow limitation by the GOLD grading
system) is positively associated with the degree of the
inflammatory response,6 and the narrowing and disap-
pearance of the small conducting airways.7 In addition,
prospective cohort studies have shown that airway and
systemic inflammation, independent of smoking,
increases the risk of worsening lung function and exacer-
bations, which, in turn, are associated with reduced
survival.8 Another cohort study observed decreases in
airway and systemic inflammation in COPD patients
hospitalized for acute exacerbation at the time of dis-
charge (i.e. after treatment and recovery).9 Although
there is considerable uncertainty about the origin and
role of inflammation in COPD, this body of evidence
suggests that new therapies for reducing the chronic
inflammatory response might improve COPD prognosis.
Low dietary intake of omega-3 fatty acids may be a
novel reversible risk factor for chronic inflammation, and
subsequent functional decline, in COPD patients,
through a variety of mechanisms, including cell surface
and intracellular receptors, that control inflammatory cell
signalling and gene expression.10 The major food sour-
ces of omega-3 fatty acids – docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA) – are fish, fish
oils and animal tissues (brain), whereas some plant oils
contain a-linolenic acid (ALA).11 Omega-6 fatty acids are
predominately derived from plant oils, although small
amounts of animal tissues contain g-linoleic acid (GLA)
and arachidonic acid.11 Omega-3 and omega-6 fatty
acids have competitive (inhibiting) interactions that2 International Journal of Evidence-Based
niversity of Adelaide, Joanna Briggs Institute. Uare important in modulating inflammation.12 Epidemio-
logical evidence (cross-sectional and prospective cohort
studies) consistently shows an inverse association
between dietary intake of omega-3 fatty acids and
systemic inflammation across different populations
including people with COPD.13–16 Moreover, the most
recent systematic review and meta-analysis of relevant
randomized controlled trials (RCTs) show that short-term
marine-derived omega-3 supplementation significantly
reduces systemic inflammatory biomarkers including C-
reactive protein (CRP), interleukin 6 (IL-6) and tumour
necrosis factor a (TNF-a) in different population
groups.17 The effectiveness of omega-3 supplement-
ation for lowering inflammatory markers was most evi-
dent in patients with cardiovascular risk factors, which
are highly prevalent in COPD patients.18 In contrast, two
cross-sectional studies on omega-6 fatty acids reported
opposing associations between dietary intake of arach-
idonic acid and systemic inflammation.13,16
Although the systematic review by Li et al.17 is an
excellent synthesis of evidence on effectiveness, none of
the studies reviewed focussed on COPD patients.
Furthermore, the equivocal results reported in one
RCT raise questions about whether a reduction in chronic
inflammation with polyunsaturated fatty acid (PUFA)
supplementation is actually beneficial in patients with
COPD.19 For instance, a cross-sectional study found no
evidence of benefit and several adverse associations
between dietary intake of individual omega-3 and o-
mega-6 fatty acids and airflow limitation in a regionally
representative sample of Dutch adults.20 To our knowl-
edge, there is no completed or in-progress systematic
review of evidence on this topic. We therefore sought to
systematically assess relevant studies on the association
of dietary intake and supplementation of specific PUFAs
with inflammatory markers and functional capacity out-
comes in COPD to inform guidelines and clinical practice.Objectives
This review sought to identify the association of dietary
intake and supplementation of specific PUFAs with
chronic inflammation and functional capacity outcomes
in people with COPD. More specifically, the objectives
were the following:He
n(1) Talth
auo identify the association of low dietary intake of
omega-3 fatty acids (DHA, EPA or ALA) and/or
omega-6 (GLA or arachidonic acid) fatty acids with
chronic inflammation and functional capacity out-
comes in people with COPD compared with con-
trols (high dietary intake reference group).care  2015 University of Adelaide, Joanna Briggs Institute
thorized reproduction of this article is prohibited.





vero identify the effectiveness of omega-3 fatty acid
supplementation (containing predominantly one
or more omega-3 fatty acids) in reducing chronic
inflammation and improving functional capacity
outcomes compared with placebo/no intervention
in people with COPD.Protocol
The Joanna Briggs Institute (JBI) protocol21 has been
registered with PROSPERO, the International Prospective
Register of Systematic Reviews hosted by the Centre for




This review considered studies that included people with
chronic lung disease within the spectrum of COPD-
related diagnoses (i.e. emphysema or chronic bronchitis).
Types of intervention(s)/phenomena of interest
This review considered observational studies that evalu-
ate dietary intake of omega-3 (EPA, DHA or ALA) and/or
omega-6 fatty acids (GLA or AA), and experimental
studies that evaluate omega-3 fatty acid supplement-
ation (containing predominantly one or more omega-3
fatty acids).
Types of studies
This review considered both experimental and non-
experimental (observational) study designs including
RCTs, non-RCTs, quasi-experimental, before and after
studies, prospective and retrospective cohort studies,
case-control studies and cross-sectional studies for
inclusion.
Types of outcomes
This review considered studies that included the follow-
ing outcome measures: airway and systemic inflamma-
tory markers and functional capacity outcomes.
Inflammatory markers included, but were not limited
to, CRP, TNF-a and interleukins. Functional capacity out-
comes included, but were not limited to, exercise-based
physical performance measures (e.g. muscle strength
and endurance), and health status or health-related
quality of life (HRQoL) measures.Search strategy
The search strategy aimed to find both published and
unpublished studies. A three-step search strategy was
utilized in this review. An initial limited search of CINAHL
was undertaken followed by an analysis of the text wordsational Journal of Evidence-Based Healthcare  2015 University
sity of Adelaide, Joanna Briggs Institute. Ucontained in the title and abstract, and of the index
terms used to describe the article. A second search was
conducted independently by two reviewers using all
identified keywords and index terms across all included
databases. Thirdly, the reference list of all identified
reports and articles was searched for additional studies.
Studies published in English prior to August 2014 were
considered for inclusion in this review. When possible,
efforts were made to contact authors for information
about unpublished trials. Details and examples of full
electronic database search strategies appear in the
appendix (Appendix I).
Assessment of methodological quality
Papers selected for retrieval were assessed by two inde-
pendent reviewers for methodological quality using the
standardized critical appraisal instruments from the JBI
Meta Analysis of Statistics Assessment and Review Instru-
ment (JBI-MAStARI).22 Any disagreements that arose
between the reviewers were resolved through discussion.
Data collection
Data were extracted from papers included in the review
independently by two reviewers using the standardized
data extraction tools from JBI-MAStARI.22 The data
extracted included specific details about the interven-
tions, populations, study methods and outcomes.
Data synthesis
Since statistical pooling was not possible because of the
diverse types of studies reviewed, the findings were
presented in narrative form, including tables to aid in
data presentation, when appropriate.
Results
The search strategy identified 187 citations after dupli-
cates were removed (Fig. 1). Nine potentially eligible
citations were identified after the first screening of titles
and/or abstracts. After further screening, seven citations
were excluded resulting in two eligible studies for review
(Appendix II).
Description of studies
Study characteristics of two studies included for review
appear in Table 1. The RCT was conducted in 80 clinically
stable COPD patients admitted to an inpatient pulmon-
ary rehabilitation centre between 2000 and 2002 in the
Netherlands (Asthma Center Hornerheide, Horn, the
Netherlands).19 The RCT was conducted in predomi-
nately male patients (about 70%), with a mean age of
63 years and without malignancies, gastrointestinal or
kidney abnormalities, metabolic or endocrine diseases,of Adelaide, Joanna Briggs Institute 3
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FIGURE 1. Flowchart summarizing identification of studies included for review.
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©2015 Uand traditional ‘inflammatory diseases’. The RCT inves-
tigated the effect of nine 1-g capsules daily, containing a
total dose of 3.4 g PUFA (400mg stearidonic acid; 760mg
GLA; 1200mg ALA; 700mg EPA; 340mg DHA) on
changes in exercise capacity, lung function and systemic
inflammation outcomes at 8 weeks. All capsules were
enriched with 3.5mg/g vitamin E to ‘stabilize the oil and
to serve as an antioxidant’. The placebo-controlled com-
parison group was administered nine 1-g capsules daily,
containing 80% palm oil and 20% sunflower oil, and the
same caloric (9 kcal/capsule) and vitamin E content as
the PUFA capsules administered in the experimental
group. The PUFA supplementation significantly
improved exercise capacity compared with the control
condition [between-group difference in mean peak
workload was 9.7W (2.5–17.0; P¼ 0.009); and mean
duration was 4.3min (0.6–7.9; P¼ 0.023)]. Between-
group differences in other outcomes were not statisti-
cally significant.
The cross-sectional study was conducted in 250 out of
342 COPD patients recruited during their first hospital4 International Journal of Evidence-Based
niversity of Adelaide, Joanna Briggs Institute. Uadmission at one of the nine university hospitals in Spain
between January 2004 and March 2006. Patients had
confirmed diagnosis of COPD, and were clinically stable
for at least 3 months after discharge, and had dietary
PUFA data and outcome data available.13 They were
predominately male patients (94%), with a mean age
of 68 years. The study investigated the associations of
exposure to high daily dietary intake of specific PUFAs
and of omega-3 to omega-6 PUFA ratios with measures
of systematic inflammation, using levels of inflammatory
markers [TNF-a, IL-6, IL-8 and high-sensitivity C-reactive
protein (hs-CRP)]; the median values discriminating
between high and low level systemic inflammation. Daily
dietary PUFA intake was estimated from analysis of
dietary habits over the past 2 years. The comparison
non-exposure condition was low PUFA intake (below the
median). The study reported the following associations:
high ALA was associated with decreased odds of high
TNF-a [odds ratio (OR) 0.46, 95% confidence interval (CI)
0.21–0.99, P¼ 0.49]; high DHA/arachidonic acid was
associated with increased odds of high TNF-a (ORHealthcare  2015 University of Adelaide, Joanna Briggs Institute
nauthorized reproduction of this article is prohibited.
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©2015 U3.02, 95% CI 1.03 to 8.91, P¼ 0.045), which is in the
opposite direction to what is expected; high arachidonic
acid was associated with increased odds of high IL-6 (OR
1.96, 95% CI 1.05–3.64, P¼ 0.034) and hs-CRP (OR 1.95,
95% CI 1.03–3.66, P¼ 0.039). Other associations were
not statistically significant.
Methodological quality
The RCT was well-conducted and had 8 of the 10 quality
items (Appendix III), but lacked details about methods
used for randomization and blinding. The cross-sectional
study was well conducted and had five of the six
applicable quality items (Appendix III), but did not use
a random sampling procedure.
Discussion
On the basis of limited evidence of effectiveness from
one 8-week RCT [National Health and Medical Research
Council (NHMRC) Level II]23 conducted in the Nether-
lands19 and aetiological evidence from one cross-sec-
tional study (NHMRC Level IV) conducted in Spain,13
there is only weak support for the use of omega-3 fatty
acid supplementation to reduce chronic inflammation
and some support to improve functional capacity in
COPD patients (NHMRC grade C). Specifically, there is
no evidence showing that low dietary intake of specific
omega-3 fatty acids worsens inflammation and/or func-
tion, nor evidence about the effectiveness of specific
types and combinations of omega-3 fatty acids, appro-
priate dosing and duration of treatment required for
improving inflammation and/or function. Thus, despite
their excellent safety profile, wide availability, low cost
and feasibility for implementation, recommendations for
omega-3 fatty acid supplementation in patients with
COPD should be applied with caution in country-specific
healthcare settings.
The size of the effect (i.e. benefit) of mixed omega-3
fatty acids on exercise capacity observed in the RCT was
large (increase from baseline was approximately 33%)
and would likely be clinically relevant to COPD patients24
and their clinicians.25 However, the improvements in
exercise capacity found in the RCT could not be attrib-
uted to a decrease in systemic inflammation, since no
changes were observed in plasma IL-6, TNF-a or hs-CRP.
This suggests that omega-3 fatty acids may improve
exercise capacity through other physiological mechan-
isms including improvements in endothelial function
and skeletal muscle metabolism. For example, a system-
atic review of RCTs conducted mostly in adults showed
that supplementation of omega-3 fatty acids signifi-
cantly improves endothelial function (assessed by
flow-mediated dilation and endothelium-independent6 International Journal of Evidence-Based
niversity of Adelaide, Joanna Briggs Institute. Uvasodilation) at a daily dose ranging from 0.45 to 4.5 g
in the short term (over a median of 56 days).26 Previous
research shows that endothelial function is a strong
predictor of exercise capacity.27–29 In addition, supple-
mentation of omega-3 fatty acids alters mitochondrial
membrane composition and respiration kinetics in
human skeletal muscle, which may improve exercise
capacity through improvements in metabolic efficiency
during exercise.30
In contrast, the lack of effectiveness for reducing
chronic inflammation is at odds with the positive find-
ings in a previous systematic review, which showed that
marine-derived omega-3 fatty acid supplementation
significantly reduced CRP, IL-6 and TNF-a levels in other
(non-COPD) population groups.17 It is possible that the
daily dose of omega-3 fatty acids in the RCT19 reviewed
was inadequate, since subgroup analysis in the system-
atic review revealed that significant reductions in hs-CRP
and TNF-a were largest in the group of studies with
dosing equal to or above the median daily dose of total
omega-3 fatty acids and EPA.17
Alternatively, the anti-inflammatory effect/benefit of
omega-3 fatty acid supplementation may have been
exaggerated and attributable to the type of placebo
used in the previous studies, resulting in bias. For
instance, subgroup analysis in the previous systematic
review revealed that the size of the effect of omega-3
fatty acids on hs-CRP was larger and statistically signifi-
cant [weighted mean difference was 0.22 (0.33 to
0.11) vs. 0.03 (0.13 to 0.20)] only when linoleic acid
(LA) (an omega-6 fatty acid) was the major fatty acid
used for placebo rather than oleic acid (an omega-9 fatty
acid).17 High (above median) daily dietary intake of LA
was associated with increased crude odds of high hs-CRP
(OR 1.67, 95% CI 1.02–2.76) in the cross-sectional study
reviewed herein.13 Conversely, the RCT evidence
reviewed herein suggests that LA supplementation
(8 g of safflower oil daily for 16 weeks) effectively reduces
serum CRP levels. Given the conflicting effectiveness
evidence on inflammation, the degree of bias, if any,
attributable to the use of LA as placebo is unclear.
Several limitations require further consideration.
Limitations in the RCT reviewed herein include analysis
of study completers, use of a placebo containing poten-
tially pro-inflammatory supplements (palm oil)31,32 and
that results may not be relevant to other COPD popu-
lations (patients with common comorbidities, and in
other countries). Limitations of the cross-sectional study
include recall bias and uncertainty about the applica-
bility of the results to other COPD populations (female
patients, patients with recent or frequent exacerbations
and other countries). Finally, reviewer-level limitationsHealthcare  2015 University of Adelaide, Joanna Briggs Institute
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the citations excluded, and the existence of other
relevant studies not identified by the search strategy,
potentially resulting in bias. However, this level of bias
was likely minimal since the results and conclusions
reported in the three citations excluded because
complete information could not be retrieved, were
conflicting.
Conclusion
Collectively, the results of this review provide weak
support for the routine use of omega-3 fatty acid supple-
mentation for reducing chronic inflammation, and some
support for improving functional capacity in COPD
patients. Furthermore, there was no consistent evidence
showing that low dietary intake of specific omega-3 fatty
acids worsens inflammation and/or function. The gener-
ation of new research evidence should focus on the
effectiveness of specific types and combinations of
omega-3 fatty acids, the appropriate doses and duration
of treatment required to improve inflammation and/or
function and on the risks or benefits of low dietary intake
of specific PUFAs, with a view to informing healthcare
policy makers, COPD patients and their clinicians.
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Appendix I: Search strategy
The databases searched were: PubMed, CINAHL, MEDLINE, EMBASE, The Cochrane Library, ProQuest Dissertations &
Theses, Scopus, Google scholar, Trove, and WHO International Clinical Trials Registry Platform (ICTRP).
Search keywords were mapped to database headings where possible and included:
Omega-3 fatty acids
Omega-6 fatty acids
Long-chain polyunsaturated fatty acids (LCPUFA)
Polyunsaturated fatty acids (PUFA)

































chronic obstructive pulmonary disease
Pulmonary Disease, Chronic Obstructive
emphysema
pulmonary emphysema.
Examples of full electronic database search strategies:
CINAHL:
’Omega-6 fatty acids’ OR ‘Omega-3 fatty acids’ OR ‘nutritional supplement’ OR (MH ‘Dietary Supplements’) OR
‘dietary intervention’ OR ‘dietary modification’ OR ‘nutritional intervention’ (MH ‘Nutrition’) OR (MH ‘Diet’) OR (MH
‘Linseed Oil’) OR ‘flaxseed oil’ OR ‘krill oil’ OR ‘squid oil’ OR ‘egg oil’ OR (MH ‘Fish’) OR ‘Fish’ OR (MH ‘Fish Oils’) OR (MH
‘Fatty Acids, Omega-6’) OR (MH ‘Fatty Acids, Omega-3’) OR (MH ‘Fatty Acids’) OR (MH ‘Arachidonic Acids’) OR
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‘arachidonic acid’ OR (MH ‘Linoleic Acids’) OR ‘linoleic acid’ OR (MH ‘alpha-Linolenic Acid’) OR ‘a-linolenic acid’ (MH
‘Eicosapentaenoic Acid’) OR (MH ‘Docosahexaenoic Acids’) OR ‘docosahexaenoic acid’ OR LCPUFA OR PUFA OR EFA OR
DHA OR ‘free fatty acids’ (MH ‘Fatty Acids, Essential’) OR ‘Essential fatty acids’ OR ‘Polyunsaturated fatty acids’ OR (MH
‘Fatty Acids, Unsaturated’) OR ‘Long-chain polyunsaturated fatty acids’
AND
bronchitis OR (MH ‘Bronchitis’) OR ‘obstructive pulmonary’ OR ‘obstructive lung’ OR ‘airflow obstruction’ OR (MH
‘Lung Diseases, Obstructive’) OR ‘chronic obstructive airway disease’ OR COAD OR COPD OR C.O.P.D. OR ‘chronic
obstructive pulmonary disease’ OR (MH ‘Pulmonary Disease, Chronic Obstructive’) OR emphysema OR ‘pulmonary
emphysema’ OR (MH ‘Emphysema’)
(NB MH¼CINAHL heading search)
MEDLINE via Ovid:
Omega-3 fatty acids.mp. or Fatty Acids, Omega-3/ OR Omega-6 fatty acids.mp. or Fatty Acids, Omega-6/ OR Fatty
Acids, Unsaturated/ or Long-chain polyunsaturated fatty acids.mp. OR Polyunsaturated fatty acids.mp. OR Fatty Acids,
Essential/ OR free fatty acids.mp. or Fatty Acids, Nonesterified/ OR Docosahexaenoic Acids/ OR Eicosapentaenoic Acid/
OR alpha-Linolenic Acid/ OR Linoleic Acid/ OR Arachidonic Acid/ OR Fatty Acids/ OR Fishes/ OR Fish Oils/ OR egg oil.mp.
OR squid oil.mp. OR krill oil.mp. OR flaxseed oil.mp. or Linseed Oil/ OR Diet/ OR nutrition.mp. OR nutritional
intervention.mp. OR Nutritional Status/ OR dietary modification.mp. or Food Habits/ OR dietary intervention.mp.
OR Dietary Supplements/ OR nutritional supplement.mp.
AND
COPD.mp. or Pulmonary Disease, Chronic Obstructive/ OR chronic lung disease.mp. OR Bronchitis/ OR ‘obstructive
pulmonary’.mp. OR ‘obstructive lung’.mp. OR Airway Obstruction/ or Lung Diseases, Obstructive/ or airflow obstruc-
tion.mp. OR ‘chronic obstructive OR airway disease’.mp. OR COAD.mp. OR Emphysema/ OR Pulmonary Emphysema/
OR Dyspnea/ OR Bronchitis, Chronic/ OR ‘chronic obstructive pulmonary disease’.mp.
(NB mp ¼ keyword search, all other terms mapped to MESH headings)
PubMed:
- (COPD[MeSH Terms]) AND Omega-3 fatty acids[MeSH Terms] OR Omega-6 fatty acids[MeSH Terms]
- (COPD) AND Omega-3 fatty acids
- (COPD AND Omega-3 fatty acids OR Omega-6 fatty acids[Title/Abstract])
- ((chronic inflammation OR chronic lung disease[Title/Abstract])) AND (AND Omega-3 fatty acids OR n-3 OR w-3 OR
Omega-6 fatty acids OR n-6 OR w-6[Title/Abstract])
Embase:
- (((COPD or ‘chronic obstructive pulmonary disease’) and Omega-3 fatty acids) or Omega-6 fatty acids).mp.
- (((COPD or ‘chronic obstructive pulmonary disease’) and Omega-3 fatty acids) or Omega-6 fatty acids).m_titl.
- (COPD or ‘chronic obstructive pulmonary disease’).ab,ti. AND (’Omega-6 fatty acids’ or n-6).mp. or w-6.ab,ti.
- (COPD.mp. or ‘chronic obstructive pulmonary disease’.ab,ti.) AND ‘Long-chain polyunsaturated fatty acids’.ab,ti.
- (COPD.mp. or ‘chronic obstructive pulmonary disease’.ab,ti.) AND ‘Polyunsaturated fatty acids’.mp. or PUFA.ab,ti.
- (COPD.mp. or ‘chronic obstructive pulmonary disease’.ab,ti.) AND ‘Essential fatty acids’.mp. or EFA.ab,ti.
- (COPD.mp. or ‘chronic obstructive pulmonary disease’.ab,ti.) AND DHA.mp. or ‘docosahexaenoic acid’.ab,ti.
- (COPD.mp. or ‘chronic obstructive pulmonary disease’.ab,ti.) AND ‘eicosapentaenoic acid’.mp. or EPA
- (COPD.mp. or ‘chronic obstructive pulmonary disease’.ab,ti.) AND ‘a-linolenic acid’.mp. or ALA
- (COPD.mp. or ‘chronic obstructive pulmonary disease’.ab,ti.) AND ‘linoleic acid’.mp. or LA.ab,ti.
- COPD.mp. or ‘chronic obstructive pulmonary disease’.ab,ti.) AND (Fish or ‘fish oil’ or ‘egg oil’ or ‘squid oil’ or ‘krill
oil’).mp. or ‘flaxseed oil’.ab,ti.
Appendix II: Excluded citations/records with reasons.
Barr RG. The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial. 2008.
Reason: Citation for a registered trial.
Barr RG, Campos H, Ahmed F, Austin JH, Biancardi A, Henschke C et al. Higher N-3 PUFA levels predict a lower rate of
respiratory exacerbations and exacerbation-related hospitalizations: A prospective cohort study. American journal of
respiratory and critical care medicine. 2011;183 (1 MeetingAbstracts).
Reason: Incomplete retrieval of information for assessment of methodological quality, data extraction, and
data synthesis
E Atlantis and B Cochrane
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Bottle L, Engel B, Hart K, Klopper T. The efficacy of dietetic intervention in patients with chronic obstructive
pulmonary disease... Selected abstracts from the British Dietetic Association Conference 2008. Journal of Human
Nutrition & Dietetics. 2008;21(4):381-2.
Reason: Incomplete retrieval of information for assessment of methodological quality, data extraction, and
data synthesis
Fulton AS, Hill AM, Williams MT, Howe PR, Frith PA, Wood LG et al. Feasibility of omega-3 fatty acid supplementation
as an adjunct therapy for people with chronic obstructive pulmonary disease: study protocol for a randomized
controlled trial. Trials. 2013;14:107. doi:10.1186/1745-6215-14-107.
Reason: Citation for a study protocol.
Metin S, Kiziltan G, Ucar N, Saka M. Nutritional support with omega-3 rich diets improve inflammation, respiratory
functions and exercise capacity in stable COPD. Annals of Nutrition and Metabolism. 2013;63:1169. doi:http://
dx.doi.org/10.1159/000354245.
Reason: Incomplete retrieval of information for assessment of methodological quality, data extraction, and
data synthesis
Novgorodtseva TP, Denisenko YK, Zhukova NV, Antonyuk MV, Knyshova VV, Gvozdenko TA. Modification of the fatty
acid composition of the erythrocyte membrane in patients with chronic respiratory diseases. BioMed research
international. 2013;12:117.
Reason: Did not meet inclusion criteria (no COPD control group).
Thomashow M, A., Yip N, H., Parikh M, Burkart K, M., Lo Cascio C, M., Shimbo D et al. Randomization To Omega-3
Polyunsaturated Fatty Acid Supplementation And Endothelial Function In Chronic Obstructive Pulmonary Disease: The
COD-Fish Pilot Randomized Controlled Trial. American Thoracic Society International Conference: American Thoracic
Society; 2014. p. A6016-A.
Reason: Incomplete retrieval of information for assessment of methodological quality, data extraction, and
data synthesis
Appendix III: Methodological quality items assessed using JBI-MAStARI instruments.
Randomized Control Trial / Cross-sectional Study
Citation Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10
Broekhuizen et al. (2005), The Netherlands U Y Y N Y Y Y Y Y Y
de Batlle et al. (2012), Spain N Y Y Y NA NA NA Y Y
Notes: Y, yes; N, no; U, unclear, NA, not applicable.
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